About the Authors
- Vivian Chen
-
Affiliation BioNovo, Inc., Emeryville, California, United States of America
- Richard E. Staub
-
Affiliation BioNovo, Inc., Emeryville, California, United States of America
- Sylvia Fong
-
Affiliation BioNovo, Inc., Emeryville, California, United States of America
- Mary Tagliaferri
-
Affiliation BioNovo, Inc., Emeryville, California, United States of America
- Isaac Cohen
-
Affiliation BioNovo, Inc., Emeryville, California, United States of America
- Emma Shtivelman
-
* E-mail: emmas@bionovo.com
Affiliation BioNovo, Inc., Emeryville, California, United States of America
Competing Interests
The authors acknowledge that they are paid employees and stock holders of BioNovo, Inc, and that this study, in its entirety, was supported by funds from BioNovo. Bezielle (BZL101) is Bionovo's proprietary botanical drug candidate (FDA-IND: 59,521) for the treatment of metastatic breast cancer. Bionovo's United States Patent No. 7,700,136 covers a method of treating breast cancer using an extract of Scutellaria Barbata. This patent also covers the use of Bionovo's proprietary BezielleR formulation as a monotherapy for the treatment of breast cancer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: ES RS. Performed the experiments: VC ES RS SF. Analyzed the data: ES RS IC MT. Wrote the paper: ES.